TICKERNERD
Menu
PCVXPCVXHealthcare · Biotechnology

PCVX Stock Forecast: Vaxcyte, Inc. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$67
−9.65% on the day

The 10 Wall Street analysts covering Vaxcyte, Inc. hold a median 12-month price target of $100 — +49.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 6 Oct 2026 — in the upper half.

Market cap
$11.0B
Ticker Nerd rank
52 / 100
Median analyst target
$100
Analysts covering
10
Revenue$0.0
Operating income−$302.8M
Net income−$284.3M
Free cash flow−$237.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+17.7%
1M
+9.1%
YTD
+44.6%
1Y
+61.9%
From 52W high
−9.6%
From 52W low
+65.4%
$40
$74
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PCVX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Vaxcyte, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
52 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
86
Momentum
84
Value
82
Quality
73
Accruals
62
Revisions
43
Issuance
25
Growth
23
Size
16

Volatility (86): The share price has been relatively steady.

Growth (23): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PCVX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PCVX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150Jan 26Apr 26Jul 26Oct 26PCVXHigh $163Median $100Low $67

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
9 Buy1 Hold0 Sell
Low $67Median $100High $163

The green dot is the last close — the median target sits +49.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
5 Oct 2026BTIGReiteratesBuy$89
5 Oct 2026GuggenheimMaintainsBuy$116 → $125
5 Oct 2026NeedhamMaintainsBuy$110 → $122
28 Sept 2026B of A SecuritiesMaintainsBuy$133 → $130
25 Sept 2026NeedhamReiteratesBuy$110
26 Feb 2026BTIGMaintainsBuy—
26 Feb 2026BTIGMaintainsBuy$85 → $89
2 Feb 2026GuggenheimReiteratesBuy—
10 Nov 2025BTIGReiteratesBuy—
16 Oct 2025BTIGMaintainsBuy—
12 Sept 2025Goldman SachsInitiatesNeutral—
22 Apr 2025Cantor FitzgeraldInitiatesOverweight—
8 Apr 2025NeedhamReiteratesBuy—
1 Apr 2025B of A SecuritiesMaintainsBuy—
1 Apr 2025Goldman SachsMaintainsBuy—
1 Apr 2025NeedhamMaintainsBuy—
12 Mar 2025GuggenheimReiteratesBuy—
26 Feb 2025GuggenheimReiteratesBuy—
26 Feb 2025NeedhamReiteratesBuy—
24 Feb 2025BTIGReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PCVX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PCVX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Vaxcyte, Inc. returned +61.9% against +17.3% for the S&P 500, dividends included.

PCVX vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Jan 26Apr 26Jul 26Oct 26PCVXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PCVX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Vaxcyte, Inc. (PCVX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.9×

Cheaper than 94% of US stocks

Price / sales
—
Price / book
3.5×

Cheaper than 28% of US stocks

EV / EBITDA
−8.4×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−36.5%

Higher than 25% of US stocks

Return on assets
−22.6%

Higher than 18% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Vaxcyte, Inc. (PCVX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Vaxcyte, Inc. has a market value of $11.0B and an enterprise value of $9.6B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$1.1B.

  • Free cash flow in the twelve months to 30 June 2026: −$921.1M.

  • Shares outstanding: 144.8M.

  • Trailing P/E: −11.9×; forward P/E: −8.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Vaxcyte, Inc. employs 507 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

PCVX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PCVXVaxcyte, Inc.$11.0B
52
KRYSKrystal Biotech, Inc.$9.7B
82
AXSMAxsome Therapeutics, Inc.$9.0B
70
PTGXProtagonist Therapeutics, Inc.$8.8B
97
IBRXImmunityBio, Inc.$10.1B
59
KYMRKymera Therapeutics, Inc.$8.8B
71
ARWRArrowhead Pharmaceuticals, Inc.$8.6B
54

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Vaxcyte, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PCVX news & analysis

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

GlobeNewsWire · 7 Oct 2026neutral

Vaxcyte priced concurrent public offerings of 7,412,500 common shares, pre-funded warrants for 400,000 shares, and $500 million in 1.50% convertible senior notes due 2032. Underwriters also received 30-day options to cover over-allotments: up to 1,171,875 additional shares and $75 million in additional notes.

Why it matters — The offerings provide details of planned financing through equity, pre-funded warrants and convertible debt, including potential over-allotment amounts.

Vaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027

Seeking Alpha · 6 Oct 2026positive

Vaxcyte reported robust phase 3 OPUS-1 results for VAX-31, showing non-inferiority to Prevnar 20 and Capvaxive in adults. The excerpt also notes OPUS-2 and OPUS-3 adult phase 3 data and phase 2 infant data are expected in the first half of 2027.

Why it matters — The results and planned 2027 readouts are key clinical developments for investors tracking VAX-31 and its potential pneumococcal strain coverage.

Vaxcyte's VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial

MarketBeat · 6 Oct 2026positive

Vaxcyte announced that its investigational 31-valent pneumococcal conjugate vaccine, VAX-31, met all pre-specified primary immunogenicity endpoints in the pivotal Phase III OPUS-1 trial conducted in adults. The trial results represent a key development milestone for the vaccine candidate.

Why it matters — For Vaxcyte watchers, meeting all primary endpoints in this pivotal Phase III trial is a significant step for VAX-31's clinical development and potential regulatory progression.

Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

GlobeNewsWire · 5 Oct 2026negative

Vaxcyte announced it has commenced underwritten public offerings of $500 million of common stock and pre-funded warrants, plus $500 million of convertible senior notes due 2032, in separate offerings, with options for underwriters to purchase up to an additional $75 million of each. Completion of each offering is not contingent on the other and remains subject to market conditions.

Why it matters — The announcement signals potential shareholder dilution from the issuance of new common stock, pre-funded warrants, and convertible notes, which PCVX watchers would monitor for its effect on share value.

Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate Transcript

Seeking Alpha · 5 Oct 2026neutral

Vaxcyte, Inc. (PCVX) hosted a discussion covering top-line results from the OPUS-1 Phase 3 trial of its VAX-31 pneumococcal vaccine candidate. The item is a transcript of that discussion of the trial results.

Why it matters — PCVX watchers would care because the OPUS-1 Phase 3 top-line results for VAX-31 provide key clinical data on a core pipeline candidate.

FAQ

Frequently asked questions about PCVX stock

What is the PCVX stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Vaxcyte, Inc. have a median 12-month price target of $100, with estimates ranging from $67 to $163. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PCVX stock a buy right now?

Of the 10 analysts covering Vaxcyte, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vaxcyte, Inc. 52 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PCVX?

As at 6 Oct 2026, Vaxcyte, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (86 of 100).

Will PCVX stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +49.2% from the last close, and Ticker Nerd's factor model ranks Vaxcyte, Inc. 52 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PCVX stock forecast for 2030?

No analyst covering Vaxcyte, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PCVX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $67 to $163 over the next 12 months.

How has PCVX stock performed over the past year?

Vaxcyte, Inc. returned +61.9% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Vaxcyte, Inc. do?

Vaxcyte Inc. is a clinical-stage vaccine company focused on developing next-generation vaccines for bacterial infectious diseases.

What is the latest news on PCVX?

The most recent item we track (GlobeNewsWire, 7 Oct 2026): "Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes". Vaxcyte priced concurrent public offerings of 7,412,500 common shares, pre-funded warrants for 400,000 shares, and $500 million in 1.50% convertible senior notes due 2032. Underwriters also received 30-day options to cover over-allotments: up to 1,171,875 additional shares and $75 million in additional notes.

Company

About Vaxcyte, Inc.

Vaxcyte Inc. is a clinical-stage vaccine company focused on developing next-generation vaccines for bacterial infectious diseases. The company uses its proprietary cell-free protein synthesis platform to design and produce optimized protein carriers and antigens, supporting the creation of conjugate and protein-based vaccine candidates. Its current pipeline centers on pneumococcal programs aimed at preventing invasive pneumococcal disease, along with additional candidates targeting other serious bacterial conditions. Vaxcyte Inc. operates in the biotechnology and infectious disease markets, where its work addresses areas with significant unmet medical need. Based in San Carlos, California, the company is known for its emphasis on broad-spectrum vaccine design and advanced manufacturing methods that differ from conventional cell-based approaches.

CEO Mr. Grant E. Pickering M.B.A. · 507 employees · United States · https://vaxcyte.com